- Home
- ASST vs ELVN Comparison
ASST vs ELVN Comparison
Compare ASST & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASST | ELVN |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.1M | 1.1B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASST | ELVN |
|---|---|---|
| Price | $0.95 | $26.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.50 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 96.0M | 1.4M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,512,106.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 125.01 | N/A |
| 52 Week Low | $0.73 | $13.30 |
| 52 Week High | $7.89 | $29.98 |
Technical Indicators
Market Signals| Indicator | ASST | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 71.86 |
| Support Level | $0.89 | $24.29 |
| Resistance Level | $1.17 | $27.42 |
| Average True Range (ATR) | 0.11 | 2.30 |
| MACD | 0.02 | 1.20 |
| Stochastic Oscillator | 51.93 | 80.06 |
Price Performance
Historical ComparisonAbout ASST Asset Entities Inc. Class B
Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.